What is Compugen?
Compugen operates as a clinical-stage therapeutic discovery and development company, distinguished by its reliance on broadly applicable, predictive computational discovery platforms. Unlike traditional drug discovery models that often rely on iterative laboratory testing, Compugen utilizes sophisticated algorithms to identify novel drug targets, specifically within the complex field of cancer immunotherapy. This data-driven methodology allows the firm to navigate the intricate landscape of immune-oncology with greater precision, identifying potential therapeutic interventions that might otherwise remain obscured. By integrating computational biology with clinical development, the company maintains a robust pipeline aimed at addressing significant unmet medical needs in oncology, effectively positioning itself as a high-value partner for larger pharmaceutical entities seeking innovative, target-rich portfolios.
How much funding has Compugen raised?
Compugen has raised a total of $71M across 2 funding rounds:
Stock Offering
$51M
Stock Offering
$20M
Stock Issuance/Offering (2014): $51M, investors not publicly disclosed
Stock Issuance/Offering (2021): $20M led by Bristol-Myers Squibb
Key Investors in Compugen
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical leader focused on the discovery and development of innovative medicines for oncology, cardiovascular disease, and immunoscience.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Compugen?
With the recent capital injection, Compugen is well-positioned to scale its clinical operations and deepen its research into next-generation immunotherapies. The strategic focus will likely center on advancing its lead candidates through rigorous clinical trials while simultaneously expanding the utility of its computational platforms to identify new, high-potential targets. As the company matures, the emphasis will shift toward validating its discovery engine through successful clinical outcomes, which will be pivotal in securing future partnerships or potential licensing agreements. The firm's ability to maintain its technological edge in computational discovery will be the primary driver of its long-term valuation, as it seeks to transform the standard of care for patients battling complex malignancies.
See full Compugen company page
